Access Industries, a U.S.-based industrial group with long-term holdings worldwide, has established its early-stage venture investment arm focused on the therapeutics space.
Access BridgeGap Ventures will fund early-stage startups and create spinoffs around potential high-impact technologies related to human therapeutics, including pharmaceuticals, biopharmaceuticals and therapeutic devices. Led by Daniel Behr, MBA, and Ben Bronstein, MD, and based in Cambridge, MA, Access BridgeGap expects to fund 3-5 companies per year and to deploy $75M over the first few years.
Fund’s advisors include:
– William Koster, PhD, former Senior Vice President for worldwide drug discovery research and early clinical development at Bristol Myers Squibb, and former President and CEO of Neurogen;
– Manuel Navia, PhD., former Vice President at Vertex, Executive Vice President at Essential Therapeutics, and founder and CEO of Althexis; and
– Isaac Kohlberg, Chief Technology Development Officer at Harvard University.
Founded in 1986 by Chairman Len Blavatnik, Access Industries focuses on sectors including natural resources and chemicals; telecommunications and media; and real estate.